Plain-English translation of NCT06845319 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
NeoCARD is testing a combination of , , and immunotherapy drugs given before surgery for people with triple-negative breast cancer who have existing heart conditions or are at high risk for heart damage from cancer treatment. Most standard breast cancer chemotherapy uses drugs called anthracyclines, which can harm the heart—so this trial uses safer alternatives instead. The goal is to shrink tumors effectively while protecting your heart.
Many people with triple-negative breast cancer also have heart problems, making standard chemotherapy too risky for them. This study exists to give these patients a treatment option that fights their cancer effectively without putting their heart in further danger.
You likely qualify if…
You likely don't qualify if…
You would receive chemotherapy and immunotherapy treatment (given intravenously) before breast surgery, with regular clinic visits and heart monitoring by a cardiologist. Treatment typically lasts several months before you have surgery to remove the tumor. Throughout the study, you'll have blood tests, imaging scans, and heart function tests to ensure the treatment is working and to monitor for any side effects.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States